Jupiter Neurosciences (JUNS) announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims ...

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3. “By ...

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3.

While several biologic agents that block IL-1β are currently approved for therapeutic use, blocking IL-1β alone only addresses one of the pathways important for NLRP3-driven diseases.

With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3. "By ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology ...

Also, the differentially expressed proteins between HS and I/R groups were shown to be displayed as UCHL5 and were mainly enriched in the NLRP3 inflammasome pathway. However, further elucidation ...

AZM-152 works by blocking the NLRP3 inflammasome, a crucial inflammatory pathway involved in BPD and other diseases. This compound specifically targets the receptor for hyaluronan-mediated ...